Operational Summary
for the Fiscal Year Ended March 31, 2020
May 13, 2020
Mitsubishi Chemical Holdings Corporation
Table of Contents
Consolidated Financial Statements for FY2019 Page No. References 1 Page No.
Number of Subsidiaries and Affiliates, Overseas
Statements of Operations 4 19
Sales Revenue, and Core Operating Income
Sales Revenue and Core Operating Income
5 Statements of Operations [Quarterly Data] 20
by Business Segment
Sales Revenue and Core Operating Income
Analysis of Core Operating Income 6 21
by Business Segment [Quarterly Data]
Overview of Business Segments 7 Special Items [Quarterly Data] 22
Capital Expenditure, Depreciation & Amortization,
Special Items 11 R&D Expenses, and Number of Employees 23
by Business Segment
Cash Flows 12 Trend of Performance 24
Statements of Financial Positions 13 Trend of Financial Position 25
FY2020 Forecasts Page No. Business Segment Information 26
Statement of Operations 15 References 2 Page No.
Consolidated Financial Results for the Fiscal Year
Sales Revenue and Core Operating Income 16 Ended March 31, 2020 (MTPC) 28
Dividend Forecast 17
Mitsubishi Chemical Holdings Corporation has adopted IFRS starting with FY2016 1Q. 2
List of Abbreviations
FY2020 April 1, 2020 – March 31, 2021
1st Half (1H): April 1, 2020 – September 30, 2020
2nd Half (2H): October 1, 2020 – March 31, 2021
FY2019 April 1, 2019 – March 31, 2020
1st Quarter (1Q): April 1, 2019 – June 30, 2019
2nd Quarter (2Q): July 1, 2019 – September 30, 2019
3rd Quarter (3Q): October 1, 2019 – December 31, 2019
4th Quarter (4Q): January 1, 2020 – March 31, 2020
1st Half (1H): April 1, 2019 – September 30, 2019
2nd Half (2H): October 1, 2019 – March 31, 2020
FY2018 April 1, 2018 – March 31, 2019
MCHC Mitsubishi Chemical Holdings Corporation
MCC Mitsubishi Chemical Corporation
MTPC Mitsubishi Tanabe Pharma Corporation
LSII Life Science Institute, Inc.
TNSC Taiyo Nippon Sanso Corporation
3
Consolidated Statements of Operations
Exchange Rate (¥/$) 108.7 109.2 109.0 111.1 (2.1) (2%)
Naphtha Price (¥/kl) 42,800 43,100 42,900 49,400 (6,500) (13%)
(Billions of Yen)
1H 2H FY2019 FY2018 Difference %
Sales Revenue 1,827.7 1,752.8 3,580.5 3,840.3 (259.8) (7%)
Continuing Operations * 2
Core Operating Income *1 130.8 64.0 194.8 314.1 (119.3) (38%)
Special Items (0.2) (50.3) (50.5) (19.3) (31.2)
Operating Income 130.6 13.7 144.3 294.8 (150.5) (51%)
Financial Income/Expenses (8.2) (14.1) (22.3) (10.0) (12.3)
(Dividend included above) [3.0] [1.2] [4.2] [5.2] [(1.0)]
(Foreign Exchange Gain/Loss included above) [0.4] [(4.1)] [(3.7)] [0.4] [(4.1)]
Income before Taxes 122.4 (0.4) 122.0 284.8 (162.8)
Income Taxes (37.6) (14.7) (52.3) (70.5) 18.2
Net Income from Continuing Operations 84.8 (15.1) 69.7 214.3 (144.6)
Net Income from Discontinued Operations *3 16.9 - 16.9 2.4 14.5
Net Income 101.7 (15.1) 86.6 216.7 (130.1)
Net Income Attributable to Owners of the Parent 81.3 (27.2) 54.1 169.5 (115.4) (68%)
Net Income Attributable to Non-Controlling Interests 20.4 12.1 32.5 47.2 (14.7)
*1 Share of profit of associates and joint ventures included. 8.1 5.3 13.4 26.8 (13.4)
*2 Discontinued operations not included.
*3 Figures for FY2019, include ¥15.8 billion from gain on share exchanges after tax.
Core operating income is calculated as operating income (loss) excluding certain gains and expenses attributable to non-recurring
factors (losses incurred by business withdrawal and streamlining, etc.).
4
Sales Revenue and Core Operating Income
by Business Segment
(Billions of Yen)
FY2019 FY2018 Difference
1Q 2Q
Sales Revenue 1,827.7 1,752.8 3,580.5 3,840.3 (259.8)
Total Consolidated Core Operating Income 130.8 64.0 194.8 314.1 (119.3)
Sales Revenue 344.3 330.7 675.0 726.1 (51.1)
Functional Products
Core Operating Income 25.3 11.6 36.9 38.2 (1.3)
Sales Revenue 204.6 202.0 406.6 429.4 (22.8)
Performance Chemicals
Core Operating Income 15.2 10.5 25.7 33.1 (7.4)
Sales Revenue 548.9 532.7 1,081.6 1,155.5 (73.9)
Performance Products
Core Operating Income 40.5 22.1 62.6 71.3 (8.7)
Sales Revenue 156.6 119.8 276.4 388.8 (112.4)
MMA
Core Operating Income 25.3 (1.0) 24.3 94.4 (70.1)
Sales Revenue 271.8 262.6 534.4 606.8 (72.4)
Petrochemicals
Core Operating Income 1.8 (3.9) (2.1) 8.7 (10.8)
Sales Revenue 135.3 111.0 246.3 280.3 (34.0)
Carbon Products
Core Operating Income 8.9 (0.8) 8.1 24.9 (16.8)
Sales Revenue 563.7 493.4 1,057.1 1,275.9 (218.8)
Chemicals
Core Operating Income 36.0 (5.7) 30.3 128.0 (97.7)
Sales Revenue 419.5 423.8 843.3 732.8 110.5
Industrial Gases
Core Operating Income 44.3 43.7 88.0 63.3 24.7
Sales Revenue 205.3 207.8 413.1 462.6 (49.5)
Health Care
Core Operating Income 9.8 4.8 14.6 53.8 (39.2)
Sales Revenue 90.3 95.1 185.4 213.5 (28.1)
Others
Core Operating Income 0.2 (0.9) (0.7) (2.3) 1.6
[Inventory valuation gain/loss]
Performance Chemicals (1.1) 0.0 (1.1) (0.2) (0.9)
Petrochemicals (3.4) 3.3 (0.1) 0.6 (0.7)
Carbon Products (0.6) (1.0) (1.6) (0.1) (1.5)
Total (5.1) 2.3 (2.8) 0.3 (3.1)
*1 All figures are approximation for reference purpose only.
*2 Discontinued operations in the Health Care segment not included.
*3 Starting from FY2019, the segmentation of certain businesses and consolidated subsidiaries in MCC has been reviewed and revised
the method of allocating certain common expenses. The segment information for FY2018 is accordingly restated. 5
Analysis of Core Operating Income
(Billions of Yen)
FY2019 FY2018 Difference
Price Volume Fixed Cost Others *1
Total Consolidated 194.8 314.1 (119.3) (87.1) (40.0) 17.9 (10.1)
Performance Products 62.6 71.3 (8.7) (2.6) (12.5) 6.3 0.1
Chemicals 30.3 128.0 (97.7) (80.8) (4.7) 2.6 (14.8)
Industrial Gases 88.0 63.3 24.7 0.0 19.8 1.2 3.7
Health Care *2 14.6 53.8 (39.2) (4.3) (44.8) 7.8 2.1
Others (0.7) (2.3) 1.6 0.6 2.2 0.0 (1.2)
*1 Items included are impacts from inventory valuation gain/loss and share of profit of associates and joint ventures etc.
*2 Discontinued operations not included. Changes in
exchange rates
(5.4) (6.8) (0.3) - 1.7
Changes in foreign currency
translation included in above
(3.5)
350.0
300.0
250.0
(87.1) ＋17.9
200.0 314.1
(40.0) (10.1)
150.0 194.8
100.0
FY2018 Price Volume Fixed Cost Others FY2019
Estimated impact of COVID-19
(7.8) (including 6.0 in Chemicals segment and 1.8 in Performance Products segment) 6
Performance Products Segment
(Billions of Yen)
Functional Products
FY2019 FY2018 Difference
Although sales volumes increased in environment and living
Functional Sales Revenue 675.0 726.1 (51.1) solutions, sales volumes were down in high-performance
Sales Revenue
Products Core Operating Income 36.9 38.2 (1.3) engineering plastics and other products owing to weaker demand,
primarily for semiconductor and automotive applications.
Performance Sales Revenue 406.6 429.4 (22.8)
Chemicals Core Operating Income 25.7 33.1 (7.4) Core Operating
Sales volumes rose in environment and living solutions, but profit
was down because of reduced high-performance engineering
Performance Sales Revenue 1,081.6 1,155.5 (73.9) Income plastics and other products.
Products Core Operating Income
62.6 71.3 (8.7)
Performance Chemicals
＜Analysis of Core Operating Income＞
Revenue decreased amid a decline in the market for phenol-
72.0 polycarbonate chain materials, while the impact of scheduled
Sales Revenue
70.0 (12.5) maintenance and repairs at these production facilities being
resolved.
68.0 (2.6)
66.0 Core Operating Profit fell owing mainly to a drop in market prices for phenol-
64.0 Income polycarbonate chain materials.
＋6.3 ＋0.1
62.0
71.3
60.0
58.0 62.6
In April 2019, MCC decided to increase the annual production capacity of Soarnol
56.0 ethylene vinyl alcohol copolymer resin of consolidated subsidiary Noltex LLC by
54.0 3,000 metric tons, to 41,000 metric tons. This rise, effective in mid-2020, was in
FY2018 Price Volume Fixed Cost Others FY2019 response to rising global demand for food packaging materials.
In June 2019, MCC agreed to transfer the storage media and other global
Estimated impact of COVID-19 businesses of the Verbatim brand of Mitsubishi Chemical Media Co., Ltd., and
(1.8) (including 0.7 in Functional Products segment assets related to that consolidated subsidiary to CMC Magnetics Corporation. This
and 1.1 in Performance Chemicals segment) accord was part of business portfolio reforms under the MCHC Group’s medium-
term management plan. The transaction was completed in December that year.
MCC and Ube Industries, Ltd., concluded an agreement in March 2020 to form MCC consolidated subsidiary MC PET Film Indonesia decided in September 2019
joint venture MC Ionic Solutions Corporation to succeed their electrolyte to lift its polyester film production capacity. The move will enable the company to
manufacturing businesses in Japan and China in October 2020. One goal is to cater to optical applications for displays and to growing demand for multilayer
reinforce the operational underpinnings of these businesses by streamlining their ceramic capacitors and other industrial offerings in response to the expanding use
purchasing, production, and sales systems. Another is to bolster the of automotive electronics and a rising number of 5G-compatible base stations. Once
competitiveness of these businesses by combining their intellectual assets and the upgrade is completed at the end of 2021, annual production capacity in
technical development capabilities. Indonesia will increase from 20,000 metric tons, to 45,000 metric tons. 7
Chemicals Segment
(Billions of Yen)
FY2019 FY2018 Difference
MMA
Revenue declined amid weaker demand and a downturn in MMA
Sales Revenue 276.4 388.8 (112.4) Sales Revenue
monomer and other markets.
MMA
Core Operating Income
24.3 94.4 (70.1) Profit decreased primarily as a result of a smaller variance in
Core Operating
Sales Revenue 534.4 606.8 (72.4) prices between raw materials and products amid a market
Petrochemicals Income downturn.
Core Operating Income (2.1) 8.7 (10.8)
Sales Revenue 246.3 280.3 (34.0) Petrochemicals
Carbon Products
Core Operating Income
8.1 24.9 (16.8)
While sales volumes were up because of a smaller impact from
Sales Revenue 1,057.1 1,275.9 (218.8) scheduled maintenance and repairs at the ethylene production
Chemicals Sales Revenue
Core Operating Income
30.3 128.0 (97.7) facility, prices declined owing to lower raw materials costs and
＜Analysis of Core Operating Income＞ other factors.
Profit was down owing mainly to a smaller variance in prices
140.0 between raw materials and products amid a market downturn and
Core Operating
120.0 a deterioration of inventory valuation, notwithstanding the lower
Income impact of scheduled maintenance and repairs at the ethylene
100.0 production facility.
80.0
Carbon Products
60.0 128.0
＋2.6 Revenue was down as a result of lower prices accompanying raw
40.0 (80.8) Sales Revenue
(4.7) material cost declines and reduced needle coke sales volumes.
20.0 (14.8)
30.3 Profit decreased owing to a smaller variance between raw
0.0 Core Operating
materials and products amid a downturn in the exported coke
FY2018 Price Volume Fixed Cost Others FY2019 Income market and a reduction in needle coke sales volumes.
Estimated impact of COVID-19
(6.0) (including 2.9 in MMA, 2.2 in Petrochemicals, and 0.9 in Carbon Products) MCC and JXTG Nippon Oil & Energy Corporation established a joint venture in
November 2019 to strengthen their collaboration in petroleum refining and
petrochemicals operations at the Kashima complex in Ibaraki Prefecture, Japan. It
will endeavor to strengthen competitiveness by optimizing manufacturing in
In keeping with a July 2019 decision, MCC consolidated subsidiary Japan petrochemicals and other products. They will also explore chemical recycling
Polypropylene Corporation halted production at one polypropylene line at its technologies to reuse waste plastics as raw materials for petroleum refining and
Kashima Plant in April 2020. It made this move to reinforce its production petrochemicals.
infrastructure and rationalize amid the construction of a new polypropylene
line at the Goi Plant as part of structural reforms to bolster profitability. 8
Industrial Gases Segment
(Billions of Yen)
Industrial Gases
FY2019 FY2018 Difference
Revenue rose as a result of the impact of European
Sales Revenue and U.S. businesses acquired in the second half of
Sales Revenue 843.3 732.8 110.5 the previous fiscal year.
Industrial Gases
Core Operating Income
88.0 63.3 24.7
Profit increased owing to the impact of acquired
Core Operating
European and U.S. businesses and from the solid
＜Analysis of Core Operating Income＞ Income
performance of the U.S. gas business.
90.0 ＋3.7
85.0 ＋1.2 In January 2020, TNSC resolved to transition through an absorption-
＋19.8
type split to a holding company structure and to change its tradename
80.0 to “Nippon Sanso Holdings Corporation” as of October 1, 2020. The
goal is to build a competitive Group operating framework as a leading
75.0 player in the global industrial gas sector. This decision is subject to
approval by TNSC shareholders at an ordinary general meeting of
70.0 shareholders scheduled for June 2020 and by the relevant regulators.
88.0
65.0
60.0
63.3
55.0
50.0
FY2018 Price Volume Fixed Cost Others FY2019
9
Health Care Segment
(Billions of Yen)
Health Care
FY2019 FY2018 Difference
Revenue was down because some royalty revenue
was not recognized owing to arbitration proceedings
Sales Revenue 413.1 462.6 (49.5) Sales Revenue
relating to Gilenya, despite growth in priority products
Health Care
Core Operating Income
14.6 53.8 (39.2) in domestic ethical pharmaceuticals.
*Discontinued operations not included.
Core Operating Profit was down mainly because some Gilenya royalty
＜Analysis of Core Operating Income＞ Income revenue was not recognized.
Note:
60.0
Royalty revenue from Novartis Pharma AG for Gilenya, a treatment agent for multiple
sclerosis, was reduced, because a part of the royalty revenue was not recognized as
(44.8) sales revenue in accordance with IFRS 15 due to the start of arbitration proceedings.
50.0
(4.3)
40.0 In August 2019, LSII completed an exchange of shares with PHC
Holdings Corporation (PHCHD) after obtaining competition low-related
regulatory approval as part of a strategic capital partnership announced
30.0 in May 2019. PHCHD thereby acquired all shares of LSI Medience
53.8
Corporation. Life Science Institute obtained a 13.7% stake in PHCHD.
20.0 LSII started clinical trials in July 2019 with the Muse cell-based product
＋2.1 CL2020 in patients with spinal cord injuries. Trials previously began for
＋7.8
patients with acute myocardial infarction, ischemic stroke, and
10.0 epidermolysis bullosa. Also in July 2019, cell processing center
14.6
Tonomachi CPC was authorized to manufacture regenerative medicine
0.0 products. LSII plans to apply for marketing approval in fiscal 2020.
FY2018 Price Volume Fixed Cost Others FY2019 MTPC received approval in July 2019 from China’s National Medical
Products Administration for Edaravone (the U.S. brand name is
Radicava) for a treatment for amyotrophic lateral sclerosis. The
company previously obtained approval in Japan, Korea, the United
In March 2020, MCHC decided to transfer Qualicaps Co., Ltd., a States, Canada, and Switzerland.
consolidated subsidiary of LSII, to the High Performance Chemicals MCHC commenced a tender offer in November 2019 for MTPC to
Business domain of MCC in July 2020. Qualicaps develops, expand the latter’s drug discovery modality and otherwise tackle a
manufactures, and sells pharmaceutical and health capsules and changing medical treatment climate, generating more synergies within
pharmaceutical processing equipment. This move would help Qualicaps the Group. That company became a wholly owned subsidiary in March
strengthen its production technologies, accelerate materials 2020.
development, and bolster its sales capabilities. 10
Consolidated Special Items
(Billions of Yen)
4Q
FY2019 FY2018 Difference
Total Special Items (30.1) (50.5) (19.3) (31.2)
Impairment loss (24.5) (43.9) (11.8) (32.1)
Loss on sale and disposal of fixed assets (6.5) (9.9) (8.5) (1.4)
Special retirement expenses (0.9) (2.0) (0.9) (1.1)
Loss on sale of intercompany securities (0.0) (1.5) (0.0) (1.5)
Gain on sale of property, plant and equipment 3.5 7.9 2.5 5.4
Reversal of Impairment Loss - 1.7 - 1.7
Gain on sale of intercompany securities - 0.5 7.5 (7.0)
Others (1.7) (3.3) (8.1) 4.8
[Special Items by Business Segment]
Performance Products (0.2) (1.9) (13.4) 11.5
Chemicals (1.1) (2.4) 4.8 (7.2)
Industrial Gases 0.0 2.1 0.2 1.9
Health Care (25.2) (41.5) (5.5) (36.0)
Others (3.6) (6.8) (5.4) (1.4)
11
Consolidated Cash Flows
Based on statements
Adjusted cash flows *1
of cash flows
(Billions of Yen)
Target for
FY2019
FY2019 FY2018 FY2019 FY2018 Forecast
(announced
on May.14)
Net cash provided by (used in) operating activities 452.0 415.6 452.0 415.6 464.0
Income before taxes 147.6 288.1 147.6 288.1 278.0
Depreciation and amortization 239.8 199.3 239.8 199.3 239.0
Change in operating receivables/payables 42.7 5.1 42.7 5.1
5.0
Change in Inventories 7.1 (13.2) 7.1 (13.2)
Others 14.8 (63.7) 14.8 (63.7) (58.0)
Net cash provided by (used in) investment activities (87.6) (895.1) (205.7) (897.5) (274.0)
Capital expenditure (236.1) (230.6) (236.1) (230.6) (298.0)
Sale of assets 30.3 41.8 30.3 41.8
24.0
Investment and loans receivable, etc. 118.2 (706.3) 0.1 (708.7)
Free cash flow 364.4 (479.5) 246.3 (481.9) 190.0
Net cash provided by (used in) financing activities (450.5) 519.1
*1 Adjusted cash flows based on actual results are calculated
Interest bearing debts 37.3 629.6 by excluding cash flows from investment of surplus funds
Additional acquisition of consolidated subsidiaries' stocks *2 (399.8) (1.4) for explanatory purposes.
Dividends, etc. (88.0) (109.1)
Net increase (decrease) in cash and cash equivalents (86.1) 39.6 *2 ¥398.1 billion in additional acquisitions of MTPC shares
Effect of exchange rate changes and changes in scope of consolidation (7.2) 4.3
Cash and cash equivalents at the beginning of the period 321.5 277.6
Cash and cash equivalents at the end of the period 228.2 321.5
12
Consolidated Statements of Financial Positions
(Billions of Yen) (Billions of Yen)
Mar. 31, 2020 Mar. 31, 2019 Difference Mar. 31, 2020 Mar. 31, 2019 Difference
Cash and cash equivalents 228.2 321.5 (93.3) Interest-bearing debt 2,388.1 2,246.8 141.3
Trade receivables 698.5 855.1 (156.6) Trade payables 398.1 492.4 (94.3)
Inventories 606.5 623.0 (16.5) Other liabilities 895.1 807.4 87.7
Other current assets 216.1 342.2 (126.1) Total liabilities 3,681.3 3,546.6 134.7
Total current assets 1,749.3 2,141.8 (392.5) Shareholders' equity 1,234.5 1,381.8 (147.3)
Tangible and Intangible fixed assets 2,252.8 2,252.1 0.7 Other components of equity (64.3) (3.8) (60.5)
Total equity attributable to
Goodwill 616.8 648.8 (32.0) 1,170.2 1,378.0 (207.8)
owners of the parent
Investment and other
513.2 529.8 (16.6) Non-controlling interests 280.6 647.9 (367.3)
non-current assets
Total non-current assets 3,382.8 3,430.7 (47.9) Total equity 1,450.8 2,025.9 (575.1)
Total assets 5,132.1 5,572.5 (440.4) Total liabilities and equity 5,132.1 5,572.5 (440.4)
Net interest-bearing debt *1 2,089.9 1,736.2 353.7
Net D/E ratio 1.79 1.26 0.53
Ratio of equity attributable to owners
22.8% 24.7% (1.9%)
of the parent
ROE *2 4.2% 12.7% (8.5%)
*1 Net interest-bearing debt (End of Mar. 31, 2020)
= interest-bearing debt (2,388.1 billion yen)
- {cash and cash equivalents (228.2 billion yen) + investments of surplus funds (70.0 billion yen)}
Note： Interest-bearing debt includes lease obligations.
*2 Ratio of net income attributable to owners of the parent.
13
Consolidated Financial Results Forecasts for FY2020
14
Consolidated Statements of Operations
Assumption in calculating fiscal 2021 forecasts
Estimate a full-year impact of COVID-19 (including lower material and fuel costs) on core operating income of
around ¥80 billion, principally in the first half
(Billions of Yen)
FY2020 FY2019
Difference
1H 2H Forecast Actual %
Sales Revenue 1,509.0 1,825.0 3,334.0 3,580.5 (246.5) (7%)
Continuing Operations *
Core Operating Income 25.0 115.0 140.0 194.8 (54.8) (28%)
Special Items 3.5 (6.5) (3.0) (50.5) 47.5
Operating Income 28.5 108.5 137.0 144.3 (7.3) (5%)
Financial Income/Expenses (10.5) (12.5) (23.0) (22.3) (0.7)
Income before Taxes 18.0 96.0 114.0 122.0 (8.0)
Income Taxes (7.0) (30.0) (37.0) (52.3) 15.3
Net Income from Continuing Operations 11.0 66.0 77.0 69.7 7.3
Net Income from Discontinued Operations 0.0 0.0 0.0 16.9 (16.9)
Net Income 11.0 66.0 77.0 86.6 (9.6)
Net Income Attributable to Owners of the Parent 0.0 49.0 49.0 54.1 (5.1) (9%)
Net Income Attributable to Non-Controlling Interests 11.0 17.0 28.0 32.5 (4.5)
* Discontinued operations are not included.
15
Consolidated Sales Revenue and Core Operating Income
by Business Segment
*1 All figures are approximation for reference purpose only.
(Billions of Yen) Estimated impact of COVID-19
(Core operating income)
FY2019 Actual
FY2020 FY2019
Difference FY2020 FY2019 (Before
1H 2H Forecast Actual *2
Forecast Actual Reclassification)
Sales Revenue 1,509.0 1,825.0 3,334.0 3,580.5 (246.5) ↓ Down 69.9for Carbon down 8.6 and2Hdown 4.6 for Health Care)
(down 4.0
in 1H and
Products
in
3,580.5
Total Consolidated
Core Operating Income 25.0 115.0 140.0 194.8 (54.8) (78.5) (7.8) 194.8
Sales Revenue 290.0 358.0 648.0 680.4 (32.4) ↓ Lower sales(FPD) applications
↓ information
of automotive, construction, and electronics and
675.0
Functional Products
Core Operating Income 8.0 29.0 37.0 39.5 (2.5) (16.8) (0.7) 36.9
Sales Revenue 187.0 225.0 412.0 437.7 (25.7) ↓ Decreasedvaluation differences applications and polycarbonate
↓ inventory
sales of automotive
406.6
Performance Chemicals
Core Operating Income (1.0) 15.0 14.0 21.7 (7.7) (12.8) (1.1) 25.7
Sales Revenue 477.0 583.0 1,060.0 1,118.1 (58.1) 1,081.6
Performance Products
Core Operating Income 7.0 44.0 51.0 61.2 (10.2) (29.6) (1.8) 62.6
Sales Revenue 111.0 136.0 247.0 262.5 (15.5) ↓Reduced sales, principally in Asia
↓ 276.4
MMA
Core Operating Income 6.0 20.0 26.0 23.8 2.2 (9.9) (2.9) 24.3
Sales Revenue 161.0 288.0 449.0 534.4 (85.4) ↓ Raw materials price drop-associated inventory valuation
↓ differences and lower sales 534.4
Petrochemicals
Core Operating Income (19.0) 6.0 (13.0) (2.1) (10.9) (15.9) (2.2) (2.1)
Sales Revenue 95.0 97.0 192.0 246.6 (54.6) ↓ Lower coke and carbon product sales
↓ 246.3
Carbon products
Core Operating Income 1.0 2.0 3.0 8.1 (5.1) (7.9) (0.9) 8.1
Sales Revenue 367.0 521.0 888.0 1,043.5 (155.5) 1,057.1
Chemicals
Core Operating Income (12.0) 28.0 16.0 29.8 (13.8) (33.7) (6.0) 30.3
Sales Revenue 396.0 426.0 822.0 843.3 (21.3) ↓ Lower sales of industrial gases
↓ 843.3
Industrial Gases
Core Operating Income 34.0 46.0 80.0 88.0 (8.0) (10.6) 88.0
Sales Revenue 186.0 201.0 387.0 393.1 (6.1) ↓ Reduced activities and lower patient numbers
↓ 413.1
Health Care
Core Operating Income 1.0 (2.0) (1.0) 16.5 (17.5) (4.6) 14.6
Sales Revenue 83.0 94.0 177.0 182.5 (5.5) 185.4
Others
Core Operating Income (5.0) (1.0) (6.0) (0.7) (5.3) 0.0 (0.7)
*2 From FY2020, Qualicaps, Inc. has been reclassified from the Health Care segment to the Performance Product segment (Performance Chemicals).
In addition, the segmentation of certain businesses and consolidated subsidiaries in MCC has been reviewed and revised the method of allocating
certain common expenses. The segment information for FY2019 is accordingly restated.
16
Dividend Forecast
MCHC’s basic policy of returning profits to shareholders emphasizes enhancement of shareholder value by
increasing the value of the company. Therefore, using 30% of the medium-term level as a guideline for the
consolidated dividend payout ratio, MCHC will make stable dividend payments, while maintaining sufficient
internal reserves as resources to develop future businesses.
As announced on April 28, 2020, the Board of Directors plans to determine year-end cash dividends per
share for fiscal 2019 on May 26. The forecast for interim and year-end cash dividends per share for fiscal
2020 is ¥12, respectively. This amount is because the business climate will likely remain adverse for the
foreseeable future in view uncertainty about when the COVID-19 pandemic will abate. The projected annual
cash dividends per share would be ¥24.
FY2020 FY2019 FY2018 FY2017 FY2016
Forecast Forecast Actual Actual Actual
Interim 12 20 20 15 8
Cash dividends
Year-end 12 12 20 17 12
per share (Yen)
Total (Annual)
Annual total 24 32 40 32 20
Net income
per share (Yen)
Year-end ¥34.51 ¥38.08 ¥119.22 ¥147.14 ¥106.73
Consolidated dividend
Annual total
Total (Annual) 69.6% 84.0% 33.6% 21.7% 18.7%
pay out ratio
17
References 1
18
Number of Subsidiaries and Affiliates,
Overseas Sales Revenue, and Core Operating Income
(Number of companies)
FY2019 FY2018 FY2017 FY2016 FY2015
Number of subsidiaries and affiliates
Subsidiaries and affiliated companies 698 754 708 731 753
Companies in consolidation scope 659 705 653 592 600
Consolidated subsidiaries 510 550 515 510 522
Japan 174 193 203 193 200
Overseas 336 357 312 317 322
Joint operation 4 4 4 4 2
Affiliates accounted for by the equity method 145 151 134 78 76
Sales revenue and core operating income by geographic area
based on location of consolidated subsidiaries
Japan 2,367.8 2,595.6 2,589.6 2,408.6 2,499.0
Overseas 1,212.7 1,244.7 1,134.8 967.5 1,044.4
Sales Revenue 3,580.5 3,840.3 3,724.4 3,376.1 3,543.4
Japan 99.5 162.3 223.2 211.5 232.4
Overseas 95.3 151.8 157.3 96.0 68.0
Core Operating Income 194.8 314.1 380.5 307.5 300.4
Overseas sales revenue based on location of customers
Overseas Sales Revenue 1,534.4 1,664.6 1,547.0 1,333.6 1,430.0
42.9% 43.3% 41.6% 39.5% 40.4%
19
Statement of Operations [Quarterly Data]
Exchange Rate (¥/$) 109.5 111.9 112.6 110.3 109.7 107.7 109.3 109.1
Naphtha Price (¥/kl) 48,700 53,500 54,200 41,200 45,400 40,200 41,300 44,800
(Billions of Yen)
FY2018 FY2019
1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q
Sales Revenue 921.8 960.1 988.5 969.9 916.4 911.3 903.1 849.7
Continuing Operations * 2
Core Operating Income *1 92.3 94.9 77.6 49.3 70.1 60.7 50.2 13.8
Special Items 0.8 (2.4) 4.9 (22.6) (0.2) 0.0 (20.2) (30.1)
Operating Income 93.1 92.5 82.5 26.7 69.9 60.7 30.0 (16.3)
Financial Income/Expenses 0.9 (3.5) (2.3) (5.1) (3.3) (4.9) (7.7) (6.4)
(Dividend included above) [3.4] [0.3] [1.3] [0.2] [2.9] [0.1] [1.1] [0.1]
(Foreign Exchange Gain/Loss included above) [0.8] [0.0] [0.1] [(0.5)] [(0.3)] [0.7] [(2.8)] [(1.3)]
Income before Taxes 94.0 89.0 80.2 21.6 66.6 55.8 22.3 (22.7)
Income Taxes (22.2) (14.7) (21.6) (12.0) (18.2) (19.4) (15.7) 1.0
Net Income from Continuing Operations 71.8 74.3 58.6 9.6 48.4 36.4 6.6 (21.7)
Net Income from Discontinued Operations 0.4 0.4 0.9 0.7 0.5 16.4 - -
Net Income 72.2 74.7 59.5 10.3 48.9 52.8 6.6 (21.7)
Net Income Attributable to Owners of the Parent 58.1 62.1 45.8 3.5 37.8 43.5 (5.0) (22.2)
Net Income Attributable to Non-Controlling Interests 14.1 12.6 13.7 6.8 11.1 9.3 11.6 0.5
8.6 7.6 5.4 5.2 5.0 3.1 2.6 2.7
*1 Share of profit of associates and joint ventures included.
*2 Discontinued operations not included.
20
Sales Revenue and Core Operating Income
by Business Segment [Quarterly Data]
(Billions of Yen)
FY2018 FY2019
1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q
Sales Revenue 921.8 960.1 988.5 969.9 916.4 911.3 903.1 849.7
Total Consolidated Core Operating Income 92.3 94.9 77.6 49.3 70.1 60.7 50.2 13.8
Sales Revenue 179.1 180.5 184.5 182.0 170.2 174.1 171.0 159.7
Functional Products
Core Operating Income 13.9 9.8 11.6 2.9 12.0 13.3 8.3 3.3
Sales Revenue 107.0 109.0 109.7 103.7 102.4 102.2 101.2 100.8
Performance Chemicals
Core Operating Income 10.6 11.4 6.0 5.1 7.5 7.7 5.6 4.9
Sales Revenue 286.1 289.5 294.2 285.7 272.6 276.3 272.2 260.5
Performance Products Core Operating Income 24.5 21.2 17.6 8.0 19.5 21.0 13.9 8.2
Sales Revenue 108.3 110.6 88.9 81.0 81.0 75.6 62.9 56.9
MMA
Core Operating Income 31.0 32.5 16.3 14.6 13.8 11.5 0.7 (1.7)
Sales Revenue 134.3 158.5 167.0 147.0 134.7 137.1 137.3 125.3
Petrochemicals
Core Operating Income (0.5) 7.7 2.9 (1.4) 0.8 1.0 1.0 (4.9)
Sales Revenue 72.5 64.7 70.6 72.5 71.6 63.7 62.1 48.9
Carbon Products
Core Operating Income 5.7 5.6 6.6 7.0 6.0 2.9 1.0 (1.8)
Sales Revenue 315.1 333.8 326.5 300.5 287.3 276.4 262.3 231.1
Chemicals Core Operating Income 36.2 45.8 25.8 20.2 20.6 15.4 2.7 (8.4)
Sales Revenue 156.8 168.9 186.7 220.4 208.6 210.9 208.8 215.0
Industrial Gases Core Operating Income 13.3 13.6 15.2 21.2 21.1 23.2 22.2 21.5
Sales Revenue 115.4 113.9 131.1 102.2 107.9 97.4 116.6 91.2
Health Care Core Operating Income 19.6 14.7 20.1 (0.6) 9.3 0.5 11.0 (6.2)
Sales Revenue 48.4 54.0 50.0 61.1 40.0 50.3 43.2 51.9
Others Core Operating Income (1.3) (0.4) (1.1) 0.5 (0.4) 0.6 0.4 (1.3)
*1 All figures are approximation for reference purpose only.
*2 Discontinued operations in the Health Care segment not included.
*3 Starting from FY2019, the segmentation of certain businesses and consolidated subsidiaries in MCC has been reviewed and revised
the method of allocating certain common expenses. The segment information for FY2018 is accordingly restated. 21
Special Items [Quarterly Data]
(Billions of Yen)
FY2018 FY2019
1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q
Total Special Items 0.8 (2.4) 4.9 (22.6) (0.2) 0.0 (20.2) (30.1)
Impairment loss (0.8) (0.1) (1.6) (9.3) (0.7) (0.7) (18.0) (24.5)
Loss on sale and disposal of fixed assets (0.8) (1.8) (0.4) (5.5) (0.6) (0.5) (2.3) (6.5)
Special retirement expenses (0.2) (0.0) (0.0) (0.7) (0.0) (1.0) (0.1) (0.9)
Loss on sale of intercompany securities ‐ (0.0) ‐ ‐ ‐ (0.1) (1.4) (0.0)
Gain on sale of property, plant and equipment 2.2 0.2 0.0 0.1 0.9 1.0 2.5 3.5
Reversal of Impairment Loss ‐ ‐ ‐ ‐ ‐ 1.7 ‐ ‐
Gain on sale of intercompany securities ‐ ‐ 7.3 0.2 0.4 0.1 ‐ ‐
Others 0.4 (0.7) (0.4) (7.4) (0.2) (0.5) (0.9) (1.7)
[Special Items by Business Segment]
Performance Products (0.7) (0.4) (2.0) (10.3) 0.2 (0.4) (1.5) (0.2)
Chemicals (0.1) (0.6) 6.3 (0.8) 0.0 (1.1) (0.2) (1.1)
Industrial Gases 0.3 (0.0) ‐ (0.1) (0.6) 1.0 1.7 0.0
Health Care ‐ ‐ 1.0 (6.5) (0.0) 0.8 (17.1) (25.2)
Others 1.3 (1.4) (0.4) (4.9) 0.2 (0.3) (3.1) (3.6)
22
Capital Expenditure, Depreciation & Amortization,
R&D Expenses, and Number of Employees
by Business segment
(Billions of Yen)
Depreciation & Number of
Capital Expenditure R&D Expenses
Amortization Employees
FY2019 FY2018 FY2019 FY2018 FY2019 FY2018 FY2019
Actual Actual Actual * Actual Actual Actual Actual
Performance Products 76.3 64.8 56.7 54.9 25.0 29.6 23,713
Chemicals 57.6 71.0 64.8 60.4 10.0 10.1 8,245
Industrial Gases 74.8 72.0 86.2 58.5 3.4 3.5 19,719
Health Care 24.2 18.0 20.5 16.3 83.0 89.6 8,800
Others 7.5 5.9 10.4 6.0 12.0 10.0 9,132
Total 240.4 231.7 238.6 196.1 133.4 142.8 69,609
*Fiscal 2019 depreciation and amortization included the impact of adopting IFRS 16 (Leases).
23
Trend of Performance
(Billions of Yen)
4,250.0 400.0
380.5
350.0
4,000.0
307.5 355.7 314.1
300.4
294.8 300.0
3,750.0
3,724.4 3,840.3
268.7 268.6 250.0
3,500.0 3,580.5
3,543.4 194.8
200.0
3,376.1 211.8
3,250.0 3,334.0
140.0
144.3 150.0
169.5
156.3
3,000.0 137.0
100.0
2,750.0
50.0
51.4 54.1 49.0
2,500.0 0.0
FY2015 FY2016 FY2017 FY2018 FY2019 FY2020
Forecast
Sales Revenue Core Operating Income Operating income Net income attributable to Shareholders of the parent
24
Trend of Financial Position
(Billions of Yen)
30.0% 3.0 2,500.0
27.3%
24.5% 24.7% 2,089.9
25.0% 2.5 2,025.9
23.0% 22.8% 2,000.0 1,919.5
1,736.2
1,698.2
20.0% 1.79 2.0 1,596.2
17.8%
1,500.0 1,450.8
15.1%
15.0% 1.5 1,155.9 1,139.5
1.26 1,134.4
1.17 1,378.0
1.06 12.7% 1,000.0
1,285.8
10.0% 0.89 1.0 1,170.2
1,091.4
972.2
5.2%
4.2% 500.0
5.0% 0.5
0.0% 0.0 0.0
FY2015 FY2016 FY2017 FY2018 FY2019 FY2015 FY2016 FY2017 FY2018 FY2019
Ratio of equity attributable to owners of the parent Total equity
ROE Equity attributable to owners of the parent
Net D/E ratio Net interest-bearing debts
25
Business Segment Information
Business Business Business Sub-Segment
Domain Segment Businesses
Information,
Optical films, Electronics and displays, Acetyl
Electronics and Displays
High Performance Films Packaging films, Industrial films
Functional
Products Environment and Living Aqua and separator solutions, Infrastructure solutions and agricultural
Solutions materials
High performance engineering plastics, Fibers and textile, Carbon fiber and
Performance Performance Advanced Moldings
composite materials, Functional moldings and composites, Almina fiber and
Products Products and Composites
light metal products
Advanced Polymers Performance polymers, Engineering polymers, Sustainable resources
Performance High Performance
Performance chemicals, Performance materials, Food ingredients
Chemicals Chemicals
New Energy Lithium ion battery materials, Energy transduction materials
MMA MMA MMA
Chemicals Petrochemicals Petrochemicals Basic petrochemicals, Polyolefins, Basic chemical derivatives
Industrial
Materials
Carbon Products Carbon Carbon Products
Industrial
Industrial gases
Gases
Pharmaceuticals
Health Care Health Care
Life science
26
References 2
27
Mitsubishi Tanabe Pharma Corporation
田辺三菱製薬株式会社
FY2019 Business Results
(April 2019 - March 2020)
May 13, 2020
28
FY2019 Business Results
FY2019 Financial Results
Comparison to previous fiscal year Comparison to forecasts
FY2019 FY2018 Increase
Change Forecasts※ Achieved
(decrease)
Billion yen Billion yen Billion yen ％ Billion yen ％
Revenue 379.8 424.7 (44.9) (10.6) 376.0 101.0
(Domestic) 313.9 307.7 6.2 2.0 308.3 101.8
(Overseas) 65.8 117.0 (51.2) (43.7) 67.6 97.3
Overseas sales ratio 17.3% 27.6% 18.0%
Cost of sales 181.0 180.6 0.3 0.2 178.5 101.4
Sales cost ratio 47.7% 42.5% 47.5%
Gross profit 198.8 244.1 (45.3) (18.6) 197.5 100.7
SG&A expense 97.5 98.2 (0.6) (0.7) 99.0 98.6
R&D expense 79.4 86.5 (7.0) (8.2) 85.5 92.9
Amortization of intangible assets
associated with products
2.4 2.9 (0.4) (15.1) 2.5 99.6
Other income and expense* (0.2) (0.5) 0.3 - (0.5) -
Core operating profit 19.0 55.8 (36.7) (65.9) 10.0 190.6
Non-recurring items* (25.1) (5.5) (19.6) - 1.5 -
Operating profit* (6.0) 50.3 (56.3) (112.1) 11.5 (52.8)
Financial income and loss* (0.4) 0.1 (0.5) -
Net profit attributable to owners of the Company 0.1 37.3 (37.2) (99.6) 5.0 2.9
Average exchange rate US$ ¥108.95 ¥111.07 ¥110.00
*Brackets indicate expense and loss ※: Announced on May 10, 2019 in the financial results of FY2018
29
FY2019 Business Results
Details of Revenue
Comparison to previous fiscal year Comparison to forecasts
FY2019 FY2018 Increase
Change Forecasts※ Achieved
(decrease)
Billion yen Billion yen Billion yen ％ Billion yen ％
Sales revenue 379.8 424.7 (44.9) (10.6) 376.0 101.0
Domestic ethical drugs 304.3 298.7 5.5 1.9 298.1 102.1
Overseas ethical drugs 49.7 55.1 (5.3) (9.8) 49.6 100.1
[Radicava] 23.1 27.0 (3.9) (14.5) 22.0 105.0
Royalty revenue, etc. 17.4 63.1 (45.6) (72.4) 19.2 90.5
OTC products 3.8 3.7 0.1 2.9 4.3 89.8
Others 4.4 3.9 0.4 11.1 4.6 95.6
※: Announced on May 10, 2019 in the financial results of FY2018
30
FY2019 Business Results
Domestic Ethical Drugs
Revenue of Priority Products and Vaccines
Comparison to previous fiscal year Comparison to forecasts
FY2019 FY2018 Increase
Change Forecasts※ Achieved
(decrease)
Billion yen Billion yen Billion yen ％ Billion yen ％
Remicade 53.3 58.8 (5.4) (9.3) 51.5 103.5
Simponi 40.9 37.4 3.4 9.2 42.2 97.0
Stelara 26.0 15.2 10.8 71.0 21.6 120.1
Tenelia 15.2 15.2 0.0 0.1 15.0 101.0
Canaglu 8.8 6.7 2.1 31.1 10.4 84.9
Canalia 6.7 7.4 (0.6) (9.2) 7.2 93.4
Lexapro 14.9 14.0 0.9 6.7 14.7 101.1
Rupafin 6.7 3.4 3.3 96.9 7.5 90.1
Imusera 4.2 4.3 (0.0) (2.3) 4.2 99.4
Total of priority products 177.1 162.6 14.4 8.9 174.7 101.4
Influenza vaccine 12.6 10.2 2.3 23.1 10.7 117.2
Tetrabik 9.4 8.5 0.9 10.8 10.0 94.4
Mearubik 5.9 6.8 (0.9) (13.6) 4.8 123.2
JEBIK V 5.1 5.5 (0.3) (6.4) 4.5 112.4
Varicella vaccine 4.9 5.1 (0.1) (3.5) 5.1 94.9
Total of vaccines 38.9 37.3 1.6 4.5 36.2 107.6
Total of priority products
and vaccines 216.0 200.0 16.0 8.0 210.9 102.4
※: Announced on May 10, 2019 in the financial results of FY2018 31
FY2019 Business Results
Revenue Trends
JPY b Stelara +10.8
Simponi +3.4
Rupafin +3.3
Canaglu +2.1 Talion -1.7
Remicade -5.4 Ceredist -1.4 Radicava -3.9
-10.4 ＋1.6
＋14.4 Gilenya* -44.0
INVOKANA -2.0
-5.3
Influenza +2.3
-45.6
424.7
The impact of
NHI drug price
revision -6.0
＋0.５
Domestic ethical drugs 379.8
+5.5
* Including a decline in sales as for the amounts among the “GILENYA® Royalty” amounts which will not be recognized as sales revenue during arbitration proceedings 32
FY2020 Business Forecasts
Forecasts of FY2020
FY2020 FY2019
Increase / Decrease
forecasts※ actual
Billion yen Billion yen Billion yen ％
Revenue 383.5 379.8 3.6 1.0
(Domestic) 314.1 313.9 0.1 0.0
(Overseas) 69.4 65.8 3.5 5.4
Overseas sales ratio 18.1% 17.3%
Cost of sales 187.5 181.0 6.4 3.6
Sales cost ratio 48.9% 47.7%
Gross profit 196.0 198.8 (2.8) (1.4)
SG&A expense 99.5 97.5 1.9 2.0
R&D expense 83.5 79.4 4.0 5.1
Amortization of intangible assets
3.0 2.4 0.5 20.4
associated with products
Other income and expense* - (0.2) 0.2 -
Core operating profit 10.0 19.0 (9.0) (47.5)
Non-recurring items* 7.0 (25.1) 32.1 -
Operating profit* 17.0 (6.0) 23.0 -
Financial income and loss* 0.5 (0.4) 0.9 -
Net profit attributable to owners of the Company 8.5 0.1 8.3 -
Average exchange rate US$ ¥108.00 ¥108.95
*Brackets indicate expense and loss
※ Excluding the impact of novel coronavirus (COVID-19) infection 33
FY2020 Business Forecasts
Details of Revenue
FY2020 FY2019
Increase / Decrease
forecasts actual
Billion yen Billion yen Billion yen ％
Domestic ethical drugs 303.5 304.3 (0.8) (0.3)
Priority products 182.3 177.1 5.2 2.9
Vaccines 40.9 38.9 1.9 5.1
Long-listed drugs, etc. 80.2 88.2 (8.0) (9.1)
Overseas ethical drugs 50.9 49.7 1.1 2.4
Radicava 22.3 23.1 (0.7) (3.3)
Royalty revenue, etc. 19.8 17.4 2.4 14.1
34
FY2020 Business Forecasts
Domestic Ethical Drugs
Forecasts of Revenue of Priority Products and Vaccines
FY2020 FY2019
Increase / Decrease
Forecasts actual
Billion yen Billion yen Billion yen ％
Remicade 44.7 53.3 (8.5) (16.1)
Simponi 42.2 40.9 1.3 3.2
Stelara 32.8 26.0 6.8 26.2
Tenelia 14.9 15.2 (0.2) (1.9)
Canaglu 9.1 8.8 0.3 3.4
Canalia 9.3 6.7 2.5 38.4
Lexapro 14.6 14.9 (0.3) (2.1)
Rupafin 10.2 6.7 3.4 51.3
Imusera 4.1 4.2 (0.0) (2.3)
Total of priority products 182.3 177.1 5.2 2.9
Influenza vaccine 12.2 12.6 (0.3) (3.1)
Tetrabik 11.2 9.4 1.7 18.7
Mearubik 6.4 5.9 0.4 8.3
JEBIK V 5.3 5.1 0.1 3.4
Varicella vaccine 4.8 4.9 (0.0) (1.7)
Total of vaccines 40.9 38.9 1.9 5.1
Total of priority products and vaccines 223.2 216.0 7.2 3.3 35
Notification of Changes in the U.S. Development Plan of
VLP Vaccine (MT-2271) and an Impairment Loss
(Non-recurring Items)
As Mitsubishi Tanabe Pharma Corporation (hereinafter, “MTPC”) announced on April 28, 2020,
the change in development plan of Virus Like Particle (VLP) vaccine for the prevention of
seasonal influenza (MT-2271) in the United States which has been developed by its affiliated
company, Medicago Inc.
MT-2271 did not meet the pre-specified success criteria of the primary endpoint in the adult
population, however results demonstrated significant vaccine efficacy compared to placebo in
prevention of influenza infection. Furthermore, in the clinical study in elderly population, the
results met the success criteria of the primary endpoint, non-inferiority to comparative licensed
egg-derived vaccine in efficacy. Medicago has decided to re-evaluate its licensing strategy in
the United States following the FDAʼs decision to request an additional clinical trial and does not
plan to file an application for approval of MT-2271 in the United States.
Following this change, MTPC has decided to write off intangible assets (in-process research and
development expenses), in the amount of approximately 24 billion Japanese Yen, as an
impairment loss (non-recurring items) in the fiscal year ending in March 2020.
Since a level of efficacy has indeed been confirmed in the clinical studies compared with a
placebo or a comparator (an egg-derived vaccine), Medicago will leverage the unique
advantages of its plant-based VLP platform technology and continue to develop a Quadrivalent
VLP vaccine to prevent seasonal influenza. To further improve the efficacy demonstrated in
these studies, Medicago started to investigate the development of the product with an
adjuvant* among new development initiatives.
*An adjuvant is a substance that is used concomitantly to enhance or support the effects of drugs
and is expected to enhance immunogenicity when administered with vaccines.
36
Major Development Pipeline
Progress in FY 2019 and targets for FY 2020
Global Projects
Study code Indication Phase Progress in FY 2019 / Targets for FY 2020
Amyotrophic lateral sclerosis︓
MT-1186 ALS
P3 • Global P3 study (long-term safety study) was started in November 2019.
• Global P3 study (BouNDless study) was started in August 2019.
ND0612 Parkinson's disease P3 • 1-year treatment evaluation of long-term safety study (BeyoND study)
was completed in October 2019.
MT-7117 Erythropoietic protoporphyria P2 • Achieved POC in FY 2019. P3 study to be started in FY 2020.
MT-2990 Endometriosis P2 • Plan to complete P2 study in FY 2020.
Vasomotor symptoms
MT-8554 associated with menopause
P2 • Under preparation for P3 study. Continuing partnering activity.
• Obtained the results of P1 study in FY 2019. P1b study (in patients) was
MT-3921 Spinal cord injury P1
started in April 2020.
Late Stage Projects in Japan
MT-6548 Renal anemia Filed • J-NDA submission in July 2019. Scheduled launch in FY 2020.
Neuromyelitis optica spectrum • Licensed-in from Viela Bio, Inc. (US）in October 2019. Scheduled J-NDA
MT-0551 disorder : NMOSD
P3
in FY 2020.
Change in Development Plan
Prophylaxis of seasonal • Decided to discontinue development in US in April 2020*
MT-2271 influenza
P3
*Started to investigate the development of the product with an adjuvant.
37
Major Development Pipeline List
As of April 30, 2020
Priority Development Approv
Item Indication P1 P2 P3 Filed
areas area ed
MT-1186 Global ALS /oral suspension
ND0612 Global Parkinson's disease
Vasomotor symptoms associated with
Central MT-8554 Global preparing
menopause
nervous
system MT-3921 Global Spinal cord injury
Neuromyelitis Optica Spectrum
MT-0551 Japan preparing
Disorder
MT-5199 Japan Tardive dyskinesia
MT-7117 Global Erythropoietic protoporphyria preparing
Immuno-
MT-2990 Global Endometriosis
inflammation
MT-5547 Japan Osteoarthritis
MT-3995 Global Non-alcoholic steatohepatitis(NASH)
MT-6548 Japan Renal anemia
Diabetes and
kidney
TA-7284 Japan Diabetic nephropathy
MP-513 China Type 2 diabetes mellitus
Vaccines MT-2355 Japan 5 combined vaccine*
*Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants
38
Launch Plan for Major Development Pipeline
FY 2020 FY 2021 FY 2022 FY 2023
MCI-186 MT-1186 ND0612 Global
ALS ALS (oral suspension) Parkinson's disease
Central (China) (Global) (Global) Japan/China
nervous MT-0551 MT-5199
system Neuromyelitis Optica
Tardive dyskinesia * For global products,
Spectrum Disorder
(Japan) (Japan) indicate the year of
launch in US
MT-7117
Erythropoietic protoporphyria
Immuno-
(Global)
inflamma
tion MT-5547
Osteoarthritis
(Japan)
MT-6548 MP-513 OD tablet TA-7284
Renal anemia Type 2 diabetes mellitus Diabetic nephropathy
Diabetes (Japan) (Japan) (Japan)
and kidney MP-513
Type 2 diabetes mellitus
(China)
MT-2355
Vaccines 5 combined vaccine
(Japan)
39
Cautionary Statement
The statements contained in this presentation is based on a number of
assumptions and belief in light of the information currently available to
management of the company and is subject to significant risks and
uncertainties.
It contains information about pharmaceuticals (Include products under
development), but is not intended for advertising or medical advice.
40
The forward-looking statements are based largely on company expectations
and information available as of the date hereof, and are subject to risks and
uncertainties, which may be beyond company control.
Actual results could differ materially due to numerous factors, including without
limitation, marketing conditions and the effects of industry competition.
41